| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9258912 | Transfusion and Apheresis Science | 2005 | 5 Pages |
Abstract
Since its initial description approximately 50Â years ago, there has been an impressive evolution in therapies for hairy cell leukemia. Long-term follow-up with 2-cholorodeoxyadenosine and 2â²-deoxycoformycin demonstrates that both agents result in a high complete remission rate and overall survival. Relapse rates appear to be between 20% and 30%. Therapeutic strategies for patients with relapsed disease include retreatment with a purine analog, rituximab, or the anti-CD22 pseudomonas exotoxin A immunoconjugate, BL-22.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Martin S. Tallman, Anaadriana Zakarija,